Interview with the CSO of Bright Minds Biosciences, Dr. Jan Torleif Pedersen

Bright Minds Biosciences is a US based biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain. Bright Minds Biosciences has a strong translational science foundation to support its drug development. It has a rich and growing library of proprietary compounds targeting the 5-HT2C, 5-HT2A/C and 5-HT2A receptors. By using intelligent drug design and advanced molecular modeling, and scientifically rigorous evaluation in pre-clinical models of brain function at the network level, the team can select compounds with the best activity profile for advancing into clinical trials in patients.